The ways the firm solves coordination problems with the different stakeholders (or the varieties of capitalism of nations) affect economic performance. Institutional gearing is one of the main determinants of economic growth. Nevertheless, there are no studies that analyse the effect of varieties of capitalism on the relationship of institutional gearing and economic growth. The objective of the paper is to estimate the effect of the variety of capitalism on the relationship between the institutional gearing index and other macroeconomic control variables on the GDP per capita in a group of developed and developing countries. To do that 3 panel data models were estimated: one with fixed effects and two with random effects, for 31 countries for the period 2011-2015. We used 16 Coordinated Market Economies and Liberal Market Economies and 15 Hierarchical Market Economies. The results showed the varieties of capitalism affect the relationship between institutional gearing and economic growth. In the Coordinated Market Economies and Liberal Market Economies this effect is higher than in Hierarchical Market Economies. Governments of Hierarchical Market Economies should not only apply public policies to build functional institutions, but also encourage the positive complementarities among them.

No abstract

Introduction: There is an urgent need to evaluate the factors contributing to the increased health expenditures in patients with diabetes mellitus, especially the cost of drugs used to treat Type 2 diabetes mellitus (T2DM) in economically developing countries. Methods: We compared the cost of oral antidiabetic drugs using the prices of two large Mexican pharmaceutical retail corporations. The prescribed daily dose was utilized for each drug, and the total expenditure per year was calculated. In addition, the percentage expenditure on medications concerning the total annual expenditure on DM care was considered. Results: Mean annual cost per person/year for the use of oral antidiabetic drugs ranged between US$8.9 and US$1355. We found significant differences between the cost of generic and brand versions of the same drug. Conclusion: There is an increased expenditure on the treatment of T2DM. Further, the prescription patterns as newer ones are more expensive than the older drugs, hence the newer are still under patent.